The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.
 
Shintaro Nakano
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Japan Agency for Medical Research and Development
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masataka Yagisawa
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Tetsuhito Muranaka
No Relationships to Disclose
 
Hiroshi Nakatsumi
Honoraria - Bayer Yakuhin; Lilly Japan; Ono Pharmaceutical
 
Takuro Saiki
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Kazuaki Harada
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Ichiro Iwanaga
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Chugai Pharma; Daiichi Sankyo; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TOWA; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical